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Abstract
Background: Focal treatment of Parkinson’s disease tremor by botulinum toxin type A incobotulinumtoxinA (BoNT-A) injections has been inadequately investigated and
at best provides modest relief with significant muscle weakness. Complexity of multi-joint tremulous movements results in non-individualized dosing regimens. This 38-week
open-label study used kinematic technology to guide muscle selection and improve efficacy of incobotulinumtoxinA (BoNT-A) injections for Parkinson’s disease tremor.
Methods: Participants (n528) attended study visits at weeks 0, 6, 16, 22, 32, and 38, and were injected with BoNT-A at weeks 0, 16, and 32. During each visit, clinical
tremor scales, the Unified Parkinson’s Disease Rating Scale (UPDRS) and the Fahn–Tolosa–Marin (FTM), and kinematic assessments were conducted. Participants
performed rest and postural scripted tasks with motion sensors placed over the wrist, elbow, and shoulder joints where tremor was quantified by angular root mean square
(RMS) amplitude in multiple degrees of freedom at each joint. Injection parameters were determined using the clinician’s interpretation of which muscles would contribute to
the upper limb tremor biomechanics analyzed kinematically.
Results: Kinematic measures of tremor amplitude allowed detailed segmentation of tremor into directional components at each arm joint permitting a statistically
significant decrease in mean UPDRS item 20 (rest tremor) at week 16 (p50.006) and at week 32 (p50.014), and in FTM tremor severity scores at week 6 (p50.024). Ten
participants perceived mild muscle weakness following the third treatment, which did not interfere with performing activities of daily living.
Discussion: Kinematics is a simple method for standardizing assessments and treatment of upper limb Parkinson’s disease tremor, thereby personalizing tremor therapy
and optimizing the effect of BoNT-A injections for Parkinson’s disease tremor.
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Introduction
Tremor is a cardinal sign of Parkinson’s disease (PD) and is one of
the most challenging symptoms to treat. In PD patients, tremor is
predominantly present at rest compared to posture or task-specific
movement.1–3 Tremor causes difficulty in performing daily activities
and significantly affects quality of life.4 Levodopa remains the most
potent drug for managing PD symptoms yet it results in significant
complications such as “wearing off” motor fluctuations and dyskinesia,
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and thus its use as a starting therapy for PD tremor is discouraged.5–7
Dopamine agonists and anticholinergic medications can be used
concomitantly with levodopa to treat tremor but may be accompanied
by neuropsychiatric and cognitive side effects.8,9 Deep brain stimula-
tion is an effective treatment for treating recalcitrant PD tremor, but
this is an invasive procedure and optimization of programming
parameters still remains unclear. Therefore, physicians and patients
are reluctant to use conventional pharmacotherapy as the first line of
defense for tremor. Alternative methods for treating tremor must be
considered, as an effective therapy is an enormous unmet need in
tremor-dominant PD patients.
Visual assessment of upper limb tremor is restricted by the difficultly in
separating multi-joint, whole-arm movements. Characteristics of tremor
such as severity at the fingers, wrist, elbow, and shoulder vary per patient
and voluntary tasks alter upper limb biomechanics.2 Wrist tremor is
complicated by the wrist’s ability to simultaneously flex–extend, pronate–
supinate, and deviate from side to side, commonly seen during rest and
described as a “pill-rolling” action in the hand.10 Elbow and shoulder
tremors are challenging to segment due to the size of these joints, and
consequently their small amplitude movements make a significant impact
at the most distal part of the arm. Similar to the wrist, the biomechanics of
the shoulder simultaneously moves in two directions, abduction–
adduction (Abd/Add) and flexion–extension (F/E).11 Thus, under-
standing tremor biomechanics is crucial for targeting specific muscle
groups for effective symptomatic treatment by BoNT-A injections.
Treating upper limb tremor with BoNT-A intramuscular injections
has not been widely adopted in clinical practice in PD tremor, despite
some success in reducing tremor severity and improving functional
rating scores.12,13 Limited improvements were attributed mainly to
muscle weakness. Significant muscle weakness from rigid protocols
using a fixed dose and predetermined group of muscles to inject,
regardless of the patient’s tremor characteristics, may contribute to
limb weakness and subsequent loss of function.14,15 Even with
techniques such as electromyograph- (EMG) or ultrasound-guided
needle injections that minimize toxin spread, muscle weakness can still
occur.16 Another factor contributing to the low efficacy reported in
previous studies may have been due to only having one or two
treatment cycles with short follow-up visits.17,18 The lack of objective
tremor assessments to monitor the dynamic movements at each joint
may also be a factor hindering optimization capability and therapeutic
outcome. Ultimately the selection of appropriate muscles to inject at
each joint remains the most important issue that kinematics can solve
by simplifying assessment of tremor and guide therapy.
Kinematic technology has been used to study the biomechanics of
motion in many scenarios, including gait and whole-body character-
istics.19,20 The use of such multi-sensor motion recordings for tremor
feature extraction is well understood.21 Successful focal tremor therapy
has recently been performed by using the biomechanics of tremor at
each of the three arm joints for standardizing selection of injection
parameters.21 Thus, efficacious use of BoNT-A, as a focal treatment,
requires appropriately determined injection sites and dosage per
muscle.22 To determine these parameters, a clinician can use
kinematic characterization of a patient’s upper limb tremor to select
muscles known to contribute to the joint movement. This was
investigated in the longest open label study to date involving 28 PD
participants who had received three BoNT-A injection treatments
based upon kinematically guided muscle selection criteria for upper
limb PD tremor every 16 weeks over a 38-week duration.
Methods
This open label, single-center, single-injector study (Health Canada
CTA# 178589) recruited a convenience sampling of 28 PD
participants from the London Movement Disorders Centre in
London, Ontario, who provided written consent and attended six
study visits at weeks 0, 6, 16, 22, 32, and 38 and were treated with
BoNT-A at weeks 0, 16, and 32. Treatment-naı¨ve participants were
maintained on monotherapy of BoNT-A injections for their PD
throughout the study whereas participants on treatment did not
change their medications throughout the study. Participants on stable
PD medication, with inadequate tremor relief, were assessed in the
“ON” state during study visits, at approximately the same time of the
day. Each study visit involved completion of clinical scales and
kinematic tremor measurements. BoNT-A (0.5 mL of saline per 100
unit vial) was injected into the tremor dominant limb under the
guidance of EMG using a Clavis portable EMG device (199 long 30 g
injectable EMG needle).
Study inclusion/exclusion criteria
The Western University Health Sciences Research Ethics Board
approved this clinical phase IIb pilot study protocol (REB#18445).
The first visit of the first participant and last visit of the last participant
occurred on November 2012 and August 2013, respectively. The
authors confirm that all ongoing and related trials for this drug/
intervention are now registered (ClinicalTrials.gov Identifier:
NCT02427646). The study’s progress was outlined in the
CONSORT flowchart displayed in Figure 1.
Inclusion criteria were consenting male and female participants
diagnosed with PD by the UK Brain Bank Criteria with. Hoehn and
Yahr stage 1–3 disease, aged 18–80 years, having tremor as their most
bothersome and important symptom while on stable medication
management for at least 6 months before enrolment, with no medication
withheld or adjusted during the time of the study, and BoNT-A-naı¨ve.
Participant criteria excluded those who had a history of stroke,
contraindications according to the BoNT-A drug monograph, preg-
nancy, and existing pharmacological therapy with tremor-inducing side
effects (e.g. lithium, valproate, etc.).
Clinical scale assessment
Well-established tremor severity and functional rating scales were
used as primary outcomes for measuring efficacy and tolerability of
BoNT-A injections. Participants completed the Fahn–Tolosa–Marin
(FTM) scale, consisting of parts A–C: rating tremor severity, and
writing and functional disability caused by tremor. The movement
disorders neurologist, blinded to prior results, assessed motor Unified
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Parkinson’s Disease Rating Scale (UPDRS) items 20 and 21, rest and
action tremor respectively, during injection visits. The assessor
monitored muscle weakness by measuring maximal grip strength
using a dynamometer. Participants reported any perceived muscle
weakness using a Likert scale (ranging from 0, no weakness, to 4,
severe weakness in injected arm muscles).
Kinematic assessment
Kinematic measures of tremor were conducted while participants
were in their “ON” state rather than their “OFF” state to reduce any
overestimation of tremor severity. As participants were already stable
on their oral medications, kinematic assessment was deemed to be best
determined after taking into account the optimal medication response
CONSORT 2010 Flow Diagram
Assessed for eligibility (n = 29) 
Excluded (n = 1)
♦  Not meeting inclusion criteria (n = 1) 
Lost to follow-up (give reasons) (n = 4)
♦   Change in medication, other symptoms
arose, time conflict
Discontinued intervention (give reasons) (n = 6)
♦  Muscle weakness and/or no benefit
Allocated to intervention (n = 28)
♦  Received allocated intervention (n = 28)




Non-Randomized (n = 28)
Enrollment
Figure 1. CONSORT Flow Diagram Displaying the Progress of the Study Design. Progress through the various stages of a trial including flow of
participants, number reasoning of withdrawals and the number of participants included for analysis.
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that was in the “ON” state. A series of scripted tasks was performed by
each participant while seated with motion sensor devices placed over
each arm joint (Figure 2). Wrist tremor was measured by angular
position. Electrogoniometers (SG150, Biometrics Ltd) were used to
measure the wrist in two degrees of freedom (DOF): flexion-extension
(F/E) and radial–ulnar deviation (R/U). A torsiometer (Q150,
Biometrics Ltd) was placed on the dorsal surface of the forearm to
measure wrist pronation–supination (P/S). The torsiometer provided
the third angular DOF of rotational motion about the wrist. The
relative motion of the wrist and the forearm was recorded by the
electrogoniometer. An electrogoniometer measured the elbow in one
DOF: F/E. An electrogoniometer placed on the shoulder measured
two DOF: F/E and Abd/Add. Thus, a total of four motion sensors
were required to capture each joint movement. Motion sensor data
were collected at 1500 Hz by TeleMyo 2400T G2 and PC interface
(MyoResearch XP Master Edition 1.08.09, Noraxon). Sensors were
attached using 3M hypoallergenic micropore medical grade tape (Ref
no.: 1530–1). Recordings at each joint were mutually exclusive, with
each sensor recording data only from a particular joint. Accelerometer
sensor data were additionally collected as a comparison tool to prior
studies and were not used for determining tremor composition.
Sensors captured tremor severity in angular RMS amplitude at each
arm joint producing biomechanical tremor data in multiple DOF: F/
E, P/S, and R/U in the wrist, F/E in the elbow, and F/E and Abd/
Add in the shoulder. Sensor calibration was completed with the
forearm supported and with the hand fixed against a vertical plane in
the neutral F/E, R/U, and P/S positions, and was held for 5 seconds.
Additional sensor calibration was performed with the participant’s arm
held straight while standing, the elbow extended with fingers pointing
down for five seconds. A total of four consecutive scripted tasks were
repeated three times in series (Figure 3). Twenty seconds were allotted
to each task that involved two rest positions (focusing on F/E and P/S
movements), and two postural positions (focusing on F/E and R/U
movements). Rest tasks, denoted “Rest-1” and “Rest-2” were
performed with a distraction (Figure 3A,B). Postural tasks involved
the participant extending both arms outstretched in front of the body
with palms facing downwards or inwards, denoted “posture-1” and
“posture-2”, respectively. Tremor was captured simultaneously with
the motion sensors at the middle finger and on the back of the hand
using accelerometers, but accelerometry data were not utilized for
determining injection parameters.
Injection determination
Raw angular signal data were processed using custom-written
software in MatLab (R2011a).11,21 The interpreted data sets displayed
total tremor severity measured in angular RMS amplitude at each arm
joint for each scripted task (Figure 4A), which was reviewed by the
movement disorders neurologist before injection. Kinematic analyses
provided a percentage of the directional contribution of tremor,
segmentation of tremor at the wrist and shoulder joints (the elbow
moves in one DOF), during a specific task. Focusing on each joint
individually, the movement disorders neurologist’s best clinical
judgment determined a BoNT-A dosage solely using the total tremor
amplitude measured kinematically. This selected BoNT-A dose was
divided using the percentage contribution data. Muscles selected for
injection were on the basis of the known anatomical basis of movement
at each joint. The amount of BoNT-A was allocated to appropriate
muscles for injection and thus injection patterns were determined
solely on the basis of the kinematic tremor composition and the
injector’s clinical expertise. Subsequent dosages were determined by
the injector’s comparisons of kinematic data with the previous visit.
This approach allowed the movement disorder neurologist to use the
kinematic data to individualize BoNT-A injection parameters to the
participant’s unique tremor aspects at each arm joint. This ensured
Figure 2. Kinematic Sensor Placement for Tremor Assessment. Placement of biometric motion sensors along the arm: shoulder electrogoniometer, elbow
electrogoniometer, wrist electrogoniometer. Accelerometers were placed on the forearm, hand, and third finger.
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that the most appropriate muscles were selected, making this approach
user-friendly and generalizable in the experienced clinician’s hands.
Statistical analyses
The means and standard deviations of both kinematic and clinical
data were analyzed using SPSS version 21 by performing one-way
repeated measures analysis of variance (ANOVA) using confidence
intervals of 95% (a50.05) with post hoc Bonferroni corrections for
multiple comparisons performed across all time points. Clinical scales
were represented by mean and standard deviations of the population
for each time point. The mean angular RMS tremor amplitude for
all three trials per task at each time point was log-transformed as
tremor amplitudes generated positively skewed distributions. Tremor
accelerometry values captured in the x-, y-, and z-axes for each task
were averaged per participant at each time point. Missing random
variable analysis tests were conducted to ensure incomplete data sets
for all independent variables were missing completely at random. The
means from each clinical rating scale and from the kinematic tremor
analyses that met criteria were tested for normality using the Shapiro–
Wilk test and z-score for skewness and kurtosis. The means that met
parametric analysis criteria underwent parametric ANOVA tests to
determine the presence of significant changes between time points
compared with week 0. Means that did not meet parametric test
criteria were tested using Friedman’s test. Partial eta-squared (partial
g2) was reported as an estimate of the population effect size.
Results
Participant demographics
Demographics and baseline clinical scores of the 28 PD study
participants are shown in Table 1. Following the first treatment at
week 16, 11% of participants (3/28) withdrew due to experiencing
both inadequate functional benefit and bothersome muscle weakness.
Following the second treatment at week 32 and focusing on the
remaining 89% of participants (25/28), one participant withdrew
because of unwanted weakness, and two participants failed to maintain
inclusion criteria such as lack of study attendance and medication
change. Of the remaining participants (22/28), four did not continue
past week 32 because of unwanted weakness (9%, 2/22), failed study
attendance (4%, 1/22), and change in other PD symptoms (4%, 1/22).
Thus, only a total of six PD participants (21%) experienced unwanted
weakness warranting study withdrawal following three treatments.
However, this implies that 79% of patients did not have enough
weakness to discontinue participation in the study.
Selecting Kinematically-based BoNT-A injection parameters
Kinematics was utilized to quantify two key characteristics of tremor
for optimizing BoNT-A therapy: severity of total tremor (angular RMS
amplitude) and directional contribution of the tremor at each arm
joint. Figure 4A displays a sample participant’s kinematic tremor
measures during each of the four tasks by plotting the total tremor
severity (plot 1) in the wrist, elbow, and shoulder joints and segmenting
total tremor in the wrist and shoulder joints by directional movements
of the total tremor (plot 2). The task with the largest tremor amplitude
served as a biomechanical basis for determining BoNT-A injection
parameters. The movement disorders neurologist interpreted the
kinematics by basing the total dose on total tremor severity (plots 1).
This total dose was ultimately divided among select muscles that
generated these fundamental tremulous movements, focusing on the
distribution of the total tremor in each DOF (plots 2) at each arm joint
(Figure 4B). In the example in Figure 4A, the “rest-2” task, with
forearm supported, generated the largest tremor severity at the wrist,
elbow, and shoulder joints. Thus, allocation of the total dose was
distributed according to the division of the total tremor, illustrated in
plot 2 for wrist and shoulder joints in Figure 4A.
Injection parameters were optimized solely using kinematics by
comparing the change in tremor at baseline to kinematic measures of
tremor at 6 weeks and 16 weeks after treatment. A reduction in total
Figure 3. Standard Scripted Tasks Performed by Each Participant
during Kinematic Recording Sessions. (A) Rest position (rest-1) with
relaxed forearm in lap measuring flexion–extension (F/E) wrist movements. (B)
Rest position (rest-2) with arm supported measuring P/S movements. (C)
Posture-1 position with shoulders flexed at 90˚ with arms extended anteriorly
and pronated (palms facing downwards). (D) Posture-2 position with shoulders
flexed at 90˚ with arms extended anteriorly, palms facing inwards.
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tremor during a task at the 6-week follow-up visit indicated the
appropriate muscles were targeted. An increase in BoNT-A dose was
required if the tremor could be reduced further, as quantified by
kinematics at post-treatment assessments, and there were no side
effects present, as perceived by the participant (reported on a Likert
scale). A reduction in dose was indicated by the participant when
prolonged muscle weakness was experienced in injected muscles lasting
more than 1 month, as rated by the Likert scale for muscle weakness,
and weakness was reported as functionally bothersome.
The mean total dose per arm did not significantly change between the
first and third treatments; however, the mean number of injected
muscles gradually increased (Table 2). The total dose for the second
treatment was increased for 47.6% of participants (10/21) and was
reduced for 14.2% (3/21). Of those who required an increased BoNT-A
dosing at the second treatment, at the third treatment, 10% of
participants (1/10) required a reversal of the increased BoNT-A
reverting to the original parameters and 20% of participants (2/10)
required an additional increase in the total dose. One participant whose
total dose increased at the second treatment was not injected at the third
treatment due to prolonged moderate muscle weakness. The total dose
was reduced for 13.3% of participants (2/15) whose parameters were
not altered during the second treatment though required a reduced total
dose at the third treatment.
The muscles selected and the mean administered dose per muscle
are summarized in Table 3. For the first treatment, all participants
were injected in the flexor carpi ulnaris and extensor carpi ulnaris. The
most frequently injected muscles during the second injection cycle (20/
21) were the extensor carpi ulnaris, pronator teres, and pronator
quadratus, and flexor carpi radialis, extensor carpi radialis, pronator
teres, pronator quadratus, and supinator during the third treatment
(14/15).
Clinical and kinematic efficacy results
Severity of rest tremor (UPDRS item 20) in the treated arm was
significantly reduced (F[2,40]58.378, p50.001, partial g250.295)
from 2.7¡0.6 at week 0 to 2.0¡0.8 at week 16 (p50.006) and to
2.1¡0.7 at week 32 (p50.014). Action tremor (UPDRS item 21) was
reduced in the treated arm from 1.6¡0.9 at week 0 to 0.9¡1.0
(p50.09) at week 16 and to 1.0¡0.8 at week 32, although this was not
statistically significant (F[2,40]52.832, p50.071, partial g250.124)
(Figure 5A).
The FTM part A score, indicating tremor severity, was significantly
reduced (F[5,65]52.043, p50.024, partial g250.136) at week 6
compared with week 0 (Figure 5B), although the mean total FTM part
B score assessing handwriting and pouring function did not produce a
significant reduction (F[5,60]51.820, p50.123, partial g250.132).
Twenty-five percent of participants (7/28) indicated their arm tremor
was the root source of functional disability, as opposed to other PD
symptoms interfering with activities of daily living, including eating,
drinking, and working tasks (Figure 5B). For these participants, eating
(solid food) FTM subcategory score was significantly reduced
(F[5,30]52.558, p50.048, partial g250.299) and produced strong
evidence of functional improvement from 2.3¡0.4 at week 0 to
1.3¡0.7 (p50.056) at week 38, although this was not significant as
demonstrated by Bonferroni pairwise comparisons.
Kinematics displayed a significant reduction in tremor severity at
each arm joint during rest and postural states over the treatment
course (Figure 5C). By analyzing tremor severity over all four tasks, a
statistically significant reduction in RMS tremor amplitude
(F[5,65]57.096, p,0.0005, partial g250.353), captured by motion-
sensor devices, was displayed in the wrist alone (Figure 3C); this was
observed following the initial treatment at week 6 (p50.004), at week
32 (p50.032), and following the third treatment at week 38 (p50.003).
Although tremor acceleration, represented by averaged x-, y- and z-
axes values, and joint RMS amplitudes measure tremor severity, they
indicate different characteristics. Mean finger acceleration over the
four tasks resembled a similar change in tremor severity to wrist joint
angles and significantly decreased (F[5,65]59.057, p,0.0005, partial
g250.411) following the first injection at week 6 (p50.001), following
the second treatment at week 22 (p50.028), at week 32 (p50.03), and
following the third treatment at week 38 (p50.003) (Figure 3C).
Likewise, tremor accelerometry captured at the hand demonstrated
significant reduction (F[5,65]57.786, p,0.0005, partial g250.375) at
week 6 (p50.003), week 22 (p50.006), week 32 (p50.003), and at
week 38 (p50.003) (Figure 5C). The severity of elbow tremor
amplitude significantly decreased (F[5,65]53.962, p50.003, partial
g250.234) from 0.46¡1.240 at week 0 to 0.08¡0.272 RMS at week
6 (p50.029) (Figure 5C). Shoulder RMS tremor amplitude did not
significantly change over the study course.
By analyzing the severity of tremor during each scripted task, the
mean wrist RMS tremor amplitude during “rest-1”. task did not
significantly change (F[5,65]51.422, p50.228, partial g250.099)
(Figure 5D). Although the RMS tremor measured during “rest-2”,
forearm partly pronated while supported, was significantly reduced
(F[5,65]53.740, p50.005, partial g250.223) from 1.2¡1.2 at baseline
to 0.7¡1.1 at week 6 (p50.045) and to 0.6¡0.7 at week 32 (p50.004).
The mean wrist RMS amplitude during “posture-1” was significantly
reduced (F[5,65]57.410, p,0.0005, partial g250.363) at week 6
(p50.003), week 22 (p50.026), and at week 32 (p50.05). The wrist
tremor amplitude captured during “posture-2” was significantly
reduced (F[5,65]54.205, p50.002, partial g250.244) at week 6
(p50.013). Finger acceleration significantly decreased (F[5,65]58.538,
p,0.0005, partial g250.396) during “posture-1” at week 6 (p50.005),
week 22 (p50.009), week 32 (p50.23), and at week 38 (p50.027)
(Figure 5E). Likewise, finger acceleration during “posture-2” decreased
(F[3.025,40.112]54.589, p50.007, partial g250.261) at week 6
(p50.025). During “rest-2”, finger tremor acceleration significantly
reduced (F[5,65]53.876, p50.004, partial g250.230) at week 6
(p50.023) and at week 38 (p50.005).
Side effects
The maximal grip strength was significantly reduced
(F[5,60]56.350, p,0.0005, partial g250.346) from 29.2¡9.5 kg at
week 0 to 21.8¡9.4 kg at week 22 (p50.05) and returned to baseline
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1 F 71 11 L R 170 0 2 1 2
2 M 35 7 R R 350 0 2 0 3
3 M 62 7 R R 175 0 3 0 0
4 M 79 7 R R 165 2 3.5 1 1
5 M 53 10 L R 2 3 1 2.5
6 M 43 5 L R 1 2 1 2
7 M 60 7 R R 225 1 3 1 2.5
8 M 79 14 R R 4 4 2 2
9 M 59 11 R R 275 2 2 1 1
10 F 77 9 L R 185 1 3 1 2
11 M 62 5 R R 203 2 3 0 0
12 M 66 7 R R 185 0 2.5 1 1
13 M 76 6 R R 152 1 2 0 1
14 F 54 6 R R 140 0 2 1 0
15 F 50 R R 0 3 0 2
16 F 75 R R 0 3 2 2
17 F 62 8 L R 152 2 3.5 1 2.5
18 F 47 14 R R 193 1 2 1 2
19 F 71 R R 0 2.5 1 2
20 M 80 9 R R 150 0 3.5 0 0
21 M 59 7 L R 170 0 3 0 2
22 M 69 6 R R 234 0 3.5 0 2.5
23 F 70 6 R R 165 2 2 2.5 2.5
24 M 68 14 R R 160 3 3 1 1
25 M 70 7 R R 165 0 3.5 0 3.5
26 M 69 L R 215 0 2 0 1
27 F 80 5 R R 150 1 2.5 1 1
28 F 66 L R 168 1 2.5 0 1
Mean 7F 65.5 7.5 8L 1L 188.2 0.9 2.7 0.7 1.6
¡ SD ¡ 11.5 ¡ 3.1 ¡ 47.5 ¡ 1.0 ¡ 0.6 ¡ 0.7 ¡ 0.9
Abbreviations: F, Female; L, Left; M, Male; PD, Parkinson’s Disease; R, Right; SD, Standard Deviation; UPDRS, Unified Parkinson’s Disease Rating Scale.
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Figure 4. Sample Participant Kinematic Data Readout of Tremor Generated from the Wrist, Elbow, and Shoulder Joints and Individualized
Muscle Selection Based on the Kinematic Tremor Profile and the Injector’s Best Clinical Judgment. (A) Total tremor severity (plot 1) is displayed in
angular RMS amplitude and the percentage of directional contribution of tremulous movement (plot 2) by three degrees of freedom in the wrist and by two degrees
of freedom in the shoulder joint. Error bars indicate standard deviation over three trials. (B) Injector’s interpretation of the kinematic results showing selection of total
dose allocated to wrist, elbow, and shoulder muscle groups based on tremor severity and the muscles selected on the basis of the amount of tremor present in each
degree of freedom each arm joint moves in.
Abbreviations: Fl-Ex, flexion-extension; Ra-Ul, radial-ulnar; Pr-Su, pronation-supination; Shl-Flx, shoulder flexion-extension; Shl-Abd, shoulder abduction-adduction.
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Table 2. Total Injected Dosage and Number of Muscles Injected as Determined by Injector Across all Participants
Week 0 (First Injection) Week 16 (Second Injection) Week 32 (Third Injection)
Patient BoNT-A Dose (U) No. of Muscles
Injected
BoNT-A Dose (U) No. of Muscles
Injected
BoNT-A Dose (U) No. of Muscles
Injected
1 100 6 No injection1 75 8
2 200 7 200 7 No Injection1
3 100 6 100 6 No Injection1
4 100 8 200 8 No Injection1
5 100 8 100 8 No Injection1
6 100 6 Withdrawn4 Withdrawn4
7 200 8 No Injection1 200 8
8 275 8 Withdrawn4 Withdrawn4
9 260 9 390 11 No Injection1
10 125 7 No injection2 125 7
11 140 8 175 9 No injection3
12 100 8 170 8 100 8
13 175 8 175 8 135 8
14 95 7 95 7 95 7
15 320 11 350 11 Withdrawn4
16 200 11 Withdrawn5 Withdrawn5
17 200 11 280 9 300 8
18 200 10 200 10 200 10
19 200 6 Withdrawn4 Withdrawn4
20 265 13 300 13 300 13
21 200 8 280 12 300 13
22 200 8 100 8 100 8
23 190 11 170 11 170 11
24 200 8 200 8 200 11
25 300 12 300 12 300 12
26 100 7 200 9 Withdrawn5
27 130 9 200 11 200 11
28 100 6 80 6 Withdrawn6
Mean¡SD 174.1¡66.8 8.4¡1.9 203.1¡84.4 9.1¡2.0 186.7¡79.5 9.5¡2.1
Abbreviations: BoNT-A, IncobotulinumtoxinA; SD, Standard Deviation.
Note: Dosing was in BoNT-A units.
1Participant presented with minimal tremor at visit and injector made a clinical judgment against injection.
2Participants subjectively reported prolonged mild unwanted weakness in non-injected muscles in treated arm, but had functional benefit.
3Participant perceived prolonged moderate wrist extensor weakness with limited functional benefit.
4Participant withdrew from study due to wrist extensor weakness.
5Participant withdrew from study due to lack of time commitment.
6Participant withdrew from study due to changes in Parkinson’s disease symptoms and met exclusion criteria.
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strength of 24.4¡8.8 kg at week 32 (Figure 5F). A significant change in
maximal grip strength was perceived as mild weakness in injected
muscles by participants, a mean rating of 1 out of 4 on the Likert scale
of muscle weakness. Significant change in perceived weakness
occurred following the second treatment: an increase from 0.2¡0.4
at week 0 to 1.1¡0.6 at week 22 (p50.03). This coincided with the
peak effect of BoNT-A. The mean maximal grip strength of the
untreated arm was 32.3¡11.1 kg at week 0 and remained unchanged
over the treatment course. Severity and frequency of perceived
weakness reported in the Likert scale for each time point is
summarized below in Table 4.
Discussion
Although tremor is not the most disabling symptom in PD, patients
perceive tremor as an important symptom that requires treatment.4
Benefits from recommended treatments for PD tremor are often
unsatisfactory and result in side effects of these medications.23 In
addition, for PD patients with tremor as their only troublesome
symptom, treatment with current oral medications becomes a
therapeutic dilemma as these drugs may contribute to motor
fluctuations and dyskinesia later in life. Hence, levodopa sparing
becomes an important variable to consider in treatment of tremor.
Previous studies have shown BoNT-A injections as a possible focal
treatment for tremor, although finger and wrist extensor muscle
weakness and dose-dependent limb weakness frequently
occurred.14,15,18,24,25 Brin et al.14 and Pullman et al.15 applied a
fixed-dosing regimen and subjectively determined injection sites that
resulted in the occurrence of dose-dependent hand weakness, thereby
reducing any functional efficacy of BoNT-A. Trosch and Pullman18
demonstrated in an open label study that five of the 10 PD patients
moderately improved in clinical tremor scores, although accelerometry
measures for rest tremor did not significantly change. The limitations
of these studies that reduced the effectiveness of BoNT-A therapy were
attributed to single injection studies, visually selecting muscles to inject,
or using fixed-dosing parameters regardless of the patient’s tremor
severity. As such, BoNT-A for PD tremor is not widely adopted in
clinical practice on the basis of these past results.
Table 3. Mean Injection Dosage by Arm Muscle Treated at Each Treatment Time Point
Muscles Injected First Injection (Week 0) Second Injection (Week 16) Third Injection (Week 32)
Mean¡SD No. of Patients
(n528)
Mean¡SD No. of Patients
(n521)




16.3¡7.0 24 15.6¡5.7 17 13.6¡5.8 14
Flexor carpi ulnaris 16.8¡6.7 28 16.1¡5.8 19 14.2¡5.5 13
Brachioradialis 20.0¡0.0 1 20.0¡0.0 1 20.0¡0.0 1
Extensor carpi
radialis
18.5¡8.2 24 17.5¡5.8 18 16.1¡5.4 14
Extensor carpi
ulnaris
18.6¡7.9 28 17.5¡5.8 20 16.5¡5.3 13
Pronator teres 17.4¡5.1 25 17.8¡4.9 20 15.7¡4.2 14
Pronator quadratus 16.0¡4.9 25 17.3¡5.1 20 15.4¡4.8 14
Supinator 17.3¡4.5 22 18.1¡4.8 18 16.8¡7.0 14
Biceps brachii 33.9¡10.3 23 36.3¡10.4 19 30.4¡9.7 12
Triceps 29.5¡10.1 10 32.7¡9.6 11 28.1¡9.3 8
Pectoralis major 33.3¡8.8 9 34.5¡13.0 11 28.1¡9.3 6
Teres major 25.8¡6.7 6 30.0¡12.2 8 29.2¡10.6 8
Deltoid 30.0¡9.4 4 32.0¡9.3 5 30.0¡5.5 5
Supraspinatus 28.0¡2.4 5 30.0¡5.5 5 27.5¡2.5 4
Abbreviation: SD, Standard Deviation.
Note: All the dosages are in units of BoNT-A. The mean values represent the average dose administered in the mean number of participants injected in that particular
muscle.
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The present study demonstrates that by individualizing BoNT-A
injection parameters on the basis of the biomechanical pattern of
tremor at the wrist, elbow, and shoulder joints, targeted focal therapy
greatly improved efficacy without impairing arm function. As
accelerometers placed on the hand/fingers cannot distinguish and
segment tremor originating from wrist, elbow, or shoulder joints,26 this
study simplified the complexity of tremor by utilizing sensor-based
recordings in conjunction with custom-written software to characterize
each patient’s tremor profile.27 Kinematics allows independent and
separate characterization of joint motion along the arm for every
Figure 5. IncobotulinumtoxinA Treatments Significantly Reduced Tremor Severity and Improved Arm Function in the Treated Arm of
Parkinson’s Disease Participants Reported Qualitatively and Quantitatively. (A) Unified Parkinson’s Disease Rating Scale item 20 and 21 mean scores
(max: four per arm) for rest and action tremor, respectively. (B) Fahn–Tolosa–Marin (FTM) part A score (max: 12 per arm), sum of tremor severity during rest,
posture, and action tasks, significantly decreased. FTM part C score (max: four per category), functional disability, was significantly reduced for eating tasks (N57).
(C) Angular RMS tremor amplitude (primary y-axis) and hand and finger accelerometer values (secondary y-axis) for each arm joint were averaged over two rest and
two postural tasks per time point. Significant reductions in wrist amplitude and finger accelerometry were observed. (D) Angular wrist tremor RMS amplitude and
(E) mean x-y-z tremor acceleration captured from the third finger displayed for each rest and postural task showed significant reduction. (F) Maximal grip strength
(blue line) and perceived muscle weakness (red line) yielded significant change at week 22.
Abbreviations: UPDRS, Unified Parkinson’s Disease Rating Scale; FTM, Fahn-Tolosa-Marin; RMS, root mean square.
Effective management of upper limb Parkinsonian tremor Rahimi F, Samotus O, Lee J, et al.
Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org
The Center for Digital Research and Scholarship
Columbia University Libraries/Information Services11
patient, which is not possible with visual assessments. Furthermore,
injection patterns can be tailored to each patient’s kinematics
(Figure 4) instead of depending on visual methods or using a standard
set of injections, as employed in previous studies.14
The significant, palliative effect of BoNT-A on whole-arm tremor
severity was clearly demonstrated both clinically and kinematically
(Figure 5). Kinematically determined BoNT-A parameters showed
efficacious results by observing a significant decrease (UPDRS item 20)
for all study time points following the first treatment. Action tremor
(UPDRS item 21) severity demonstrated a trending decline in rating,
although this was not significant (Figure 5A). Likewise, the FTM
tremor severity score displayed significant improvement in rest,
postural, and action tremor at week 6 that continued to week 38.
Those seven participants who found tremor to be functionally
bothersome at baseline demonstrated significantly improved eating
and function of daily tasks, a significant enhancement in quality of life
(Figure 5B). These functionally beneficial improvements in fine and
gross motor skills continued to occur following the peak effect of
BoNT-A. Reduced maximal grip strength during peak activity of
BoNT-A (Figure 5F) was not perceived to be functionally bothersome
as participants rated such weakness as a 1 out of 4 on the Likert scale,
indicating mild weakness in injected muscles. Although maximal grip
strength decreased by 25% following the first treatment and 57% of
participants (12/21) experienced third finger extensor weakness, this
was perceived as slight to mild weakness and these effects were
reported as not troublesome. This demonstrated that kinematically
based BoNT-A injection patterns minimize the likelihood of adverse
functional impairments.14 For future studies, as weakness in non-
injected muscles (e.g. finger extensors) and in injected wrist muscle
groups did occasionally occur, a need for further refinement of
injection techniques, such as incorporating ultrasound-guided injec-
tions could be considered.16
Dosages per muscle, in particular elbow and shoulder muscle groups
(Table 3), were substantially lower than previous studies involving
treatment of PD, and cerebellar and essential tremor.15 As dosing was
calculated on the basis of the quantified tremor amplitude, the best
medicated, that is “ON”, state was chosen. Thus, tremor treatment
with BoNT-A was provided concomitantly over and above the best-
treated oral medication state. Eight muscles were injected on average,
which was more than reported in previous studies.24,25 It is possible
that kinematic determination of the joint dynamics of tremor would
allow better optimization of injections, thereby reducing muscle
weakness.15
The study limitations were non-blinded injections and having no
treatment comparator, and as this was an open-label study the results
are subject to bias. As outcomes in this longitudinal study are both
qualitative and quantitative, a persistent placebo response is unlikely.
Since weakness is obvious to perceive by both the clinician and the
participant, long-term blinded studies with BoNT-A are challenging
to conduct. Validated clinical rating scales were used as primary
endpoints of this study, but a need for better functional assessment
scales, such as a patient global impression of change, could be
incorporated for future studies. Comparative studies investigating the
use of surface EMG alone versus kinematics for tremor localization
and assessment may also be useful in confirming this study’s results.
In addition, since tremor is variable, fluctuations in severity during
each visit introduced error. However, participants were assessed
around the same time of day and in the “ON” state. Visually-based
versus kinematically-based treatments were not compared as prior
studies have already shown the lack of reproducibility and tolerability
using visually guided, fixed schedule injections.11–15,17,18 The sample
size is similar to other reported studies in the literature.2,11–15,
18,21,24,25,27
This study shows that individual, objective measurement of tremor
at each joint in the upper limb affected by tremor allows for proper
characterization and treatment of PD patients. When achieved, such
characterization can be used to guide the clinician’s muscle selection
for treatment of tremor. In PD tremor, individualized and optimized
dosages of BoNT-A can be used successfully and without significant
severe weakness over a series of injections.
Table 4. Number of Participants Who Perceived Weakness Using a Likert Scale Over the Treatment Course
Time Number of Participants Per Likert Score
0 1 2 3 4
Week 0 (n518) 15 3 – – –
Week 6 (n521) 9 6 5 1 –
Week 16 (n518) 11 6 1 – –
Week 22 (n517) 4 8 5 – –
Week 32 (n519) 9 8 2 – –
Week 38 (n514) 4 8 1 1 –
Note: Likert scale scores ranged from 05 no weakness, 15 mild weakness in non-injected muscles, 25 mild weakness in injected muscles, 35 moderate weakness in
injected muscles and 4 5 severe weakness in injected muscles.
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